Bioequivalence study on Some Commercially Available Paracetamol Tablets with the innovator product: In vitro dissolution study
DOI:
https://doi.org/10.5281/zenodo.20253162Keywords:
Dissolution, Paracetamol, Dissolution ComparisonAbstract
Dissolution testing is a crucial in vitro technique in the formulation and development of pharmaceutical dosage forms. Tablets, a common dosage form, consist of a mixture of active ingredient(s), usually in powder form, with or without excipients. Acetaminophen is one of the most widely used drugs in the world. Numerous brands of acetaminophen are available commercially which are widely considered bioequivalent. The aim of the current study was to conduct a dissolution test on various products of acetaminophen tablets to assess their bioequivalence. Five different generic formulations of 500 mg paracetamol tablets from different manufacturers were selected and tested for dissolution in a 5.8 pH phosphate buffer for 30 minutes. Results were compared to those obtained from the reference product using a USP Type II dissolution testing apparatus. The dissolution testing revealed that products A, B, C, D, and E have dissolution rates of 96%, 103%, 114%, 111% and 94%, respectively, in comparison to the brand Panadol, which dissolved at 99% within 30 minutes. All tested tablets were within the pharmacopoeia criteria
Downloads
References
[1] A. Bertolini, A. Ferrari, A. Ottani, S. Guerzoni, R. Tacchi, and S. Leone, “Paracetamol: New vistas of an old drug,” CNS Drug Rev., vol. 12, no. 3–4, pp. 250–275, 2006.
[2] R. A. Granberg and Å. C. Rasmuson, “Solubility of paracetamol in pure solvents,” J. Chem. Eng. Data, vol. 44, no. 6, pp. 1391–1395, 1999, doi: 10.1021/je990124v.
[3] A. Viswanathan, D. Feskanich, E. Schernhammer, and S. Hankinson, “Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer,” Cancer Res., vol. 68, no. 7, pp. 2507–2513, 2008.
[4] B. Bryant, K. Knights, and E. Salerno, Pharmacology for Health Professionals. Marrickville, NSW, Australia: Elsevier, 2006.
[5] Joint Formulary Committee, British National Formulary (BNF 76), 76th ed. London, UK: Pharmaceutical Press, 2018.
[6] V. V. Pillay, Modern Medical Toxicology, 4th ed. New Delhi, India: Jaypee Brothers Medical Publishers, 2013.
[7] D. Gunnell, V. Murray, and K. Hawton, “Use of paracetamol (acetaminophen) for suicide and nonfatal poisoning: worldwide patterns of use and misuse,” Suicide Life Threat. Behav., vol. 30, pp. 313–326, 2000.
[8] L. J. Chun, M. J. Tong, R. W. Busuttil, and J. R. Hiatt, “Acetaminophen hepatotoxicity and acute liver failure,” J. Clin. Gastroenterol., vol. 43, pp. 342–349, 2009.
[9] World Health Organization, WHO Model List of Essential Medicines. Geneva, Switzerland: WHO, 2007.
[10] L. Lachman, H. A. Lieberman, and J. L. Kanig, The Theory and Practice of Industrial Pharmacy, 3rd ed. New Delhi, India: CBS Publishers & Distributors Pvt. Ltd., 1986.
[11] G. Bai, Y. Wang, and P. M. Armenante, “Velocity profiles and shear strain rate variability in the USP dissolution testing apparatus 2 at different impeller agitation speeds,” Int. J. Pharm., vol. 403, no. 1–2, pp. 1–14, 2011.
[12] M. E. M. Hassouna, Y. M. Issa, and A. G. Zayed, “A comparative study of the in-vitro dissolution profiles of paracetamol and caffeine combination in different formulations using HPLC,” J. Appl. Pharm. Sci., vol. 2, no. 5, pp. 52–59, 2012, doi: 10.7324/JAPS.2012.2531.
[13] United States Pharmacopeial Convention, The United States Pharmacopeia 43; The National Formulary 38. Rockville, MD, USA: United States Pharmacopeial Convention, 2020.
[14] British Pharmacopoeia Commission, British Pharmacopoeia Commission 2020: Expert Advisory Group MC1—Medicinal Chemicals, 2020.
[15] N. D. Jayram, T. Santosh, S. Jeyavijayan, M. S. Revathy, and S. Sonia, “Quality analysis and quantum classical analysis of acetaminophen,” Int. J. Eng. Adv. Technol., vol. 9, no. 1S4, pp. 360–365, Dec. 2019, doi: 10.35940/ijeat.A1180.1291S419.
[16] K. Abebe, T. B. Beressa, and B. T. Yimer, “In-vitro evaluations of quality control parameters of paracetamol tablets marketed in Gondar City, Northwest Ethiopia,” Drug Healthc. Patient Saf., vol. 12, pp. 273–279, 2020, doi: 10.2147/DHPS.S282420.
[17] K. Prakash and S. Parvez, “Comparative study of generic local brands and different multinational brands of paracetamol available in the local market of Lucknow, India,” Int. J. Res. Anal. Rev., vol. 9, no. 4, pp. 688–696, Nov. 2022.
[18] L. Teklu, E. Adugna, and A. Ashenef, “Quality evaluation of paracetamol tablets obtained from the common shops (kiosks) in Addis Ababa, Ethiopia,” Int. J. Pharm. Sci. Res., vol. 5, no. 9, pp. 3502–3510, 2014, doi: 10.13040/IJPSR.0975-8232.5(9).3502-10.
[19] J. R. Medina-Lopez, J. M. Leyva-Hernandez, J. J. Hernandez-Osornia, and J. C. Ruiz-Segura, “Simulated acetaminophen plasma profiles from fixed-dose combination formulations: studies using the flow-through cell dissolution method,” Int. J. Res. Pharm. Sci., vol. 15, no. 2, pp. 33–41, 2024.
[20] A. K. Nayak, “Comparative in vitro dissolution assessment of some commercially available paracetamol tablets,” Int. J. Pharm. Sci. Rev. Res., vol. 2, pp. 29–30, 2010.
[21] A. A. Abdulla and M. A. Oshi, “A simple approach to enhance dissolution of commercial paracetamol tablets for fast relief of pain,” BrJP, vol. 7, e20240044, 2024, doi: 10.5935/2595-0118.20240044-en.
[22] A. K. Kar and B. Kar, “In-vitro comparative dissolution study of commercially available paracetamol tablet,” J. Drug Delivery Ther., vol. 10, no. 1, pp. 18–23, 2020, doi: 10.22270/jddt.v10i1.3817.
[23] United States Pharmacopeial Convention, The United States Pharmacopeia 34; The National Formulary 29. Rockville, MD, USA: United States Pharmacopeial Convention, 2011.
[24] M. E. Aulton and K. M. G. Taylor, Eds., Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 6th ed. Elsevier, 2021.
Downloads
Published
License
Copyright (c) 2024 Al-Wataniya Private University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
